Market Place
Sourcing Support
Immix Biopharma Announces Dr. Comenzo Joins Advisory Board
19 Sep 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Vaishali Sanchorawala Joins Scientific Advisory Board
04 Jan 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Marko Radic Joins Scientific Advisory Board
18 Dec 2023 //
GLOBENEWSWIRE
Nexcella Announces 100% Overall Response Rate (n=10) for CAR-T NXC-201
11 Dec 2023 //
GLOBENEWSWIRE
Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201
21 Nov 2023 //
GLOBENEWSWIRE
Nexcella Presents NXC-201 Data at 65th ASH Annual Meeting
06 Nov 2023 //
GLOBENEWSWIRE
Nexcella Announces Dr. Michaela Liedtke Joins Scientific Advisory Board
26 Oct 2023 //
GLOBENEWSWIRE
Nexcella Completes 3rd NXC-201 Engineering Batch at CAR-T Manufacturing Site
16 Oct 2023 //
GLOBENEWSWIRE
Nexcella Announces Complete Response in NXC-201 Clinical Trial at IMS Meeting
03 Oct 2023 //
GLOBENEWSWIRE
Nexcella Announces 72-Patient NXC-201 Clinical Data
02 Oct 2023 //
GLOBENEWSWIRE
FDA Approves Orphan Drug Designation for Nexcella NXC-201
21 Sep 2023 //
GLOBENEWSWIRE
Nexcella Completes 2nd NXC-201 Engineering Batch
19 Sep 2023 //
CONTRACT PHARMA
Nexcella Completes NXC-201 Engineering Batch at U.S. CAR-T Manufacturing Site
19 Sep 2023 //
GLOBENEWSWIRE
Nexcella to Present at the Bank of America 2023 Healthcare Company Conference
07 Sep 2023 //
GLOBENEWSWIRE
FDA Approves Orphan Drug Designation for NXC-201 for Multiple Myeloma
23 Aug 2023 //
GLOBENEWSWIRE
Nexcella Announces Dr. Heather Landau Joins Nexcella Scientific Advisory Board
18 Aug 2023 //
GLOBENEWSWIRE
Nexcella Announces NXC-201 AL Amyloidosis Data Accepted for Presentation
16 Aug 2023 //
GLOBENEWSWIRE
Nexcella Announces NXC-201 Multiple Myeloma Data Accepted for Presentation
25 Jul 2023 //
GLOBENEWSWIRE
Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
26 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Edward J. Borkowski, former CFO of Mylan N.V
22 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Jeffrey H. Cooper, former CFO of BioMarin, to BOD
20 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, formerJ&J BOD
16 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Mary Sue Coleman, former J&J Director
16 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc
12 Jun 2023 //
GLOBENEWSWIRE
Nexcella Announces Commencement of NXC-201 Engineering Batches at Site
26 May 2023 //
GLOBENEWSWIRE
Nexcella reports new data for CAR-T therapy in AL amyloidosis
22 May 2023 //
CLINICAL TRIALS ARENA
Nexcella Announces Positive NXC-201 Clinical Results at ASGCT
21 May 2023 //
GLOBENEWSWIRE
Nexcella Announces Late-Breaking NXC-201 Data Abstract Oral Presentation
04 May 2023 //
GLOBENEWSWIRE
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100%
26 Apr 2023 //
GLOBENEWSWIRE
Nexcella announces presentation at European Society for 49th Annual Meeting
04 Apr 2023 //
GLOBENEWSWIRE
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 NXC-201 Efficacy
31 Mar 2023 //
GLOBENEWSWIRE
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy
31 Mar 2023 //
GLOBENEWSWIRE
Nexcella, an Immix Subsidiary, Announces New Positive NXC-201 Clinical Data
23 Mar 2023 //
GLOBENEWSWIRE
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100%
23 Mar 2023 //
GLOBENEWSWIRE
Nexcella to Discuss Recent Positive NXC-201 Clinical Data In AL Amyloidosis
06 Mar 2023 //
GLOBENEWSWIRE
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201
27 Feb 2023 //
GLOBENEWSWIRE
Nexcella Enters into U.S. Agreement to Expand NXC-201 Phase 1b/2 Trial
15 Feb 2023 //
GLOBENEWSWIRE
Nexcella Presents Data with 90% Response Rate in Relapsed Multiple Myeloma
09 Feb 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201
06 Jan 2023 //
GLOBENEWSWIRE
Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data
06 Jan 2023 //
GLOBENEWSWIRE
Nexcella announces poster at the EU Society for Blood & Marrow Transplantatio
28 Dec 2022 //
BIOSPACE
